Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Evidation

Health Tech & Medtech · San Mateo, United States · Founded 2012 Unicorn

A health data analytics platform that collects and analyzes continuous behavioral data and healthcare information

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Headcount
100–500
Current team size
Unlock exact value

Investors

16 investors on Evidation's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 5 investors entered at this stage
B Capital
Sanofi-Genzyme BioVentures
GE Ventures
Asset Management Ventures
ABS Ventures
Series A 2 investors entered at this stage
Rock Health
Fresco Capital
Series B+ 9 investors entered at this stage
Rethink Venture Capital
Kaiser Permanente Ventures
Section 32
Revelation Partners
Sanofi
Kaiser Permanente
SV Health Investors
OMERS Private Equity
McKesson Ventures

Global footprint

Where Evidation has talent and traffic

AI talent share
8.9% of workforce is AI talent
(9 of 101 staff)
Core AI54.95%
Other AI43.96%
Non-AI workforce9291.09%
Workforce by country
5 countries with
team presence
🇺🇸 United States90%
🇨🇦 Canada4.7%
🇸🇬 Singapore1.9%
🇳🇬 Nigeria1.3%
🇬🇧 United Kingdom1.2%
5 countries shown
Web traffic by country
940K monthly visits
across markets
🇺🇸 United States93.9%
🇬🇧 United Kingdom2.3%
🇳🇬 Nigeria0.4%
🇨🇦 Canada0.4%
🇦🇺 Australia0.3%
Top 5 markets shown

Market sentiment

What the market is saying about Evidation

An AI-synthesized read of the highest-engagement posts about Evidation on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Evidation on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.